巨头加价159%，抢购减肥药公司

Core Insights - Pfizer has successfully acquired the weight loss startup Metsera, with a revised offer of up to $86.25 per share, representing a 159% premium over Metsera's closing price before the initial announcement [2][11] - The acquisition is part of a competitive landscape in the weight loss drug market, where major pharmaceutical companies are vying for innovative technologies and platforms [2][10] Summary by Sections Acquisition Details - Pfizer and Metsera announced a merger agreement amendment, with the board of Metsera reaffirming support for the deal [2] - The revised offer includes an initial cash payment of $65.60 per share and potential milestone payments of up to $20.65 per share [2] - The competitive bidding process intensified after Novo Nordisk made an $8.5 billion offer for Metsera, prompting Pfizer to increase its bid [4][11] Strategic Importance - The acquisition is seen as a strategic move for Pfizer to address gaps in its pipeline, particularly after setbacks with its own GLP-1 candidates [4][6] - Metsera's value lies not only in its clinical assets but also in its three innovative technology platforms: HALO, MOMENTUM, and MINT, which have broader applications beyond weight loss [5][11] Market Context - The weight loss drug market is experiencing significant growth, with projections indicating that oral GLP-1 drugs could capture about 24% of the market by 2030 [8] - Novo Nordisk remains a dominant player in the market, with substantial revenue from its GLP-1 products, while Eli Lilly's offerings are also performing well [7][12] - The competitive landscape is evolving, with a shift from product-based competition to a focus on technological platforms and pipeline ecosystems [12][13]